Krantz, M. S., Lemoine, C., Zhou, L., King, A. J., Kroshinsky, D., Phillips, E. J., & Blumenthal, K. G. (2025). Specific clinical features define HLA-A∗32:01-positive vancomycin drug reaction with eosinophilia and systemic symptoms: A multi-institution cross-sectional study. J Allergy Clin Immunol Pract, 13(8), 2182-2185.e1. https://doi.org/10.1016/j.jaip.2025.05.027

Krantz, Matthew S., Chantal Lemoine, Li Zhou, Andrew J. King, Daniela Kroshinsky, Elizabeth J. Phillips, and Kimberly G. Blumenthal. “Specific clinical features define HLA-A∗32:01-positive vancomycin drug reaction with eosinophilia and systemic symptoms: A multi-institution cross-sectional study.” J Allergy Clin Immunol Pract 13, no. 8 (August 2025): 2182-2185.e1. https://doi.org/10.1016/j.jaip.2025.05.027.

Krantz MS, Lemoine C, Zhou L, King AJ, Kroshinsky D, Phillips EJ, et al. Specific clinical features define HLA-A∗32:01-positive vancomycin drug reaction with eosinophilia and systemic symptoms: A multi-institution cross-sectional study. J Allergy Clin Immunol Pract. 2025 Aug;13(8):2182-2185.e1.

Krantz, Matthew S., et al. “Specific clinical features define HLA-A∗32:01-positive vancomycin drug reaction with eosinophilia and systemic symptoms: A multi-institution cross-sectional study.” J Allergy Clin Immunol Pract, vol. 13, no. 8, Aug. 2025, pp. 2182-2185.e1. Pubmed, doi:10.1016/j.jaip.2025.05.027.

Krantz MS, Lemoine C, Zhou L, King AJ, Kroshinsky D, Phillips EJ, Blumenthal KG. Specific clinical features define HLA-A∗32:01-positive vancomycin drug reaction with eosinophilia and systemic symptoms: A multi-institution cross-sectional study. J Allergy Clin Immunol Pract. 2025 Aug;13(8):2182-2185.e1.